Trials / Completed
CompletedNCT00551447
A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)
A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 616 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This purpose of this study is to determine if the administration of ezetimibe and simvastatin together is more effective than simvastatin alone in lowering LDL-C levels to a goal of \<100 mg/dL in patients at risk for Heart Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653, ezetimibe / Duration of Treatment: 27 Weeks | |
| DRUG | MK0733, simvastatin / Duration of Treatment: 27 Weeks | |
| DRUG | Comparator: simvastatin / Duration of Treatment: 27 Weeks |
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2003-03-01
- Completion
- 2003-03-01
- First posted
- 2007-10-31
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00551447. Inclusion in this directory is not an endorsement.